July 28, 2018
SAN DIEGO and COPENHAGEN, Denmark, July 23, 2018 /PRNewswire/ — Dermtreat, a clinical-stage biopharmaceutical company focused on mucosal diseases, today announced treatment of the first patient in a Phase 2b clinical trial of Rivelin® Clobetasol patch (Rivelin®-CLO) for oral lichen planus (OLP). Rivelin-CLO is the first biodegradable oral adhesive patch designed for local delivery of clobetasol...


New test exposes dangerous moles
14. February 2020
Asthma is programmed early in life
7. February 2020
A female dog may well be the answer
24. January 2020


Lundbeckfonden Ventures

Lundbeckfonden Emerge